Table 2.
FRAX based 10-years probability for Hip fracture and major osteoporotic fractures, and BMD measurements at baseline of study cohort.
| Dmab group (n = 13) |
ZOL group (n = 10) |
Control (n = 14) |
p-Valued | |
|---|---|---|---|---|
| FRAX Hip (%) | 1.85 ± 0.80a | 1.99 ± 1.24a | 0.38 ± 0.53 | <0.001 |
| FRAX MOF (%) | 6.94 ± 1.64a | 4.74 ± 2.20a | 2.20 ± 0.92 | <0.001 |
| BMD L1-L4 | 1.002 ± 0.156b | 1.000 ± 0.140b | 1.200 ± 0.166 | 0.003 |
| BMD FN | 0.748 ± 0.04a | 0.763 ± 0.04a | 0.963 ± 0.08 | <0.001 |
| T-score L1-L4 | −1.79 ± 1.28b | −1.86 ± 1.17b | −0.29 ± 1.45 | 0.006 |
| T-score FN | −2.44 ± 0.30c | −2.13 ± 0.71c | −0.83 ± 0.66 | <0.005 |
FRAX, fracture risk assessment tool; MOF: major osteoporotic fracture; BMD, bone mineral density; FN, femoral neck.
a
p < 0.001 vs. Control.
b
p < 0.05 vs. Control.
c
p < 0.005 vs. Control.
d
Comparisons performed between the 3 groups. Non-parametric analysis, Kruskal-Wallis and Mann-Whitney test as applicable (with Bonferroni correction p-value: 0.05/3 = 0.017) were used for the non-normally distributed data of FRAX MOF and T-score L1-L4.